Teva’s Actavis will be able to offer a generic alternative to Bausch Health’s Xifaxan (rifaximin) 550mg tablets in the US around two years before the longest-lasting US patent protecting the gastrointestinal drug expires. Under the terms of a patent-litigation settlement that ends proceedings in a Delaware district court, Actavis can market, without royalties, its own approved generic of Xifaxan 550mg from 1 January 2028. Alternatively, from the same date, the generics firm can license restricted supplies of an authorised generic.
If another generic rifaximin product is approved in US and enters the market, Actavis will be able to launch before...



